Drug intelligence / Profile preview

SBX-1052

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBX-1052 is a natural plant-based herbal medicine under development for the control and prevention of prostatic hyperplasia (enlargement of the prostate gland). It is being developed by Stramsen Biotech, a company specializing in medicinal phytochemistry and natural products. The drug is positioned as an alternative to synthetic therapies due to rising resistance and safety concerns associated with some conventional drugs. As of May 2025, its highest global R&D status is preclinical. The mechanism of action has not been publicly disclosed.

Beyond the preview

Go deeper on SBX-1052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-1052.

Explore the full profile